BR112015014367A2 - formulações inibidoras de lfa-1 - Google Patents

formulações inibidoras de lfa-1

Info

Publication number
BR112015014367A2
BR112015014367A2 BR112015014367A BR112015014367A BR112015014367A2 BR 112015014367 A2 BR112015014367 A2 BR 112015014367A2 BR 112015014367 A BR112015014367 A BR 112015014367A BR 112015014367 A BR112015014367 A BR 112015014367A BR 112015014367 A2 BR112015014367 A2 BR 112015014367A2
Authority
BR
Brazil
Prior art keywords
lfa
inhibitor formulations
formula
treatment
methods
Prior art date
Application number
BR112015014367A
Other languages
English (en)
Other versions
BR112015014367B1 (pt
Inventor
Newman Mary
Hunke William
Original Assignee
Sarcode Bioscience Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=50979140&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=BR112015014367(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sarcode Bioscience Inc filed Critical Sarcode Bioscience Inc
Publication of BR112015014367A2 publication Critical patent/BR112015014367A2/pt
Publication of BR112015014367B1 publication Critical patent/BR112015014367B1/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Abstract

resumo “formulações inibidoras de lfa-1” a presente invenção fornece formulações, métodos e kits para o tratamento das doenças de olho seco. em particular, composições farmacêuticas estabilizadas compreendendo o composto de fórmula 1 são descritas aqui para uma variedade de usos incluindo o tratamento da síndrome de olho seco. em um aspecto, os métodos e ingredientes para melhorar a estabilidade das composições do composto de fórmula 1 são descritos.
BR112015014367-9A 2012-12-19 2013-12-18 Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular BR112015014367B1 (pt)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201261739609P 2012-12-19 2012-12-19
US61/739,609 2012-12-19
US201361758147P 2013-01-29 2013-01-29
US61/758,147 2013-01-29
PCT/US2013/076041 WO2014100135A1 (en) 2012-12-19 2013-12-18 Lfa-1 inhibitor formulations

Publications (2)

Publication Number Publication Date
BR112015014367A2 true BR112015014367A2 (pt) 2017-07-11
BR112015014367B1 BR112015014367B1 (pt) 2022-11-22

Family

ID=50979140

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112015014367-9A BR112015014367B1 (pt) 2012-12-19 2013-12-18 Composição inibidora de lfa-1, método para estabilizar a dita composição e uso da mesma para tratar uma doença ocular

Country Status (21)

Country Link
US (2) US11058677B2 (pt)
EP (2) EP2934510B1 (pt)
JP (1) JP6373867B2 (pt)
KR (1) KR101891144B1 (pt)
CN (1) CN104955453B (pt)
AU (1) AU2013361579B2 (pt)
BR (1) BR112015014367B1 (pt)
CA (1) CA2894170C (pt)
DK (1) DK2934510T3 (pt)
EA (2) EA028008B1 (pt)
ES (1) ES2846724T3 (pt)
HK (2) HK1214536A1 (pt)
HU (1) HUE052299T2 (pt)
IL (1) IL239490B (pt)
MX (2) MX368876B (pt)
NZ (1) NZ708821A (pt)
PL (1) PL2934510T3 (pt)
PT (1) PT2934510T (pt)
SI (1) SI2934510T1 (pt)
WO (1) WO2014100135A1 (pt)
ZA (2) ZA201504404B (pt)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106995439B (zh) * 2016-01-26 2019-09-20 镇江圣安医药有限公司 氘取代3-(甲磺酰基)-l-苯丙氨酸衍生物及其药物组合物、药物制剂和用途
WO2019171260A1 (en) * 2018-03-09 2019-09-12 Mankind Pharma Ltd. Pharmaceutical composition of lifitegrast
JP2022530322A (ja) 2019-04-18 2022-06-29 アズーラ オフサルミックス エルティーディー． 眼障害を処置するための化合物および方法
EP3842032A1 (en) 2019-12-24 2021-06-30 Warszawskie Zaklady Farmaceutyczne Polfa S.A. A pharmaceutical formulation

Family Cites Families (29)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2694719A (en) 1949-02-12 1954-11-16 Opplt Jan Method of stabilizing ascorbic acid with alkali-thiosulfate-carbamide-complexes
ATE147619T1 (de) * 1992-05-13 1997-02-15 Sandoz Ag Opthalmische zusammensetzungen enthaltend ein cyclosporin
US5429819A (en) * 1992-10-14 1995-07-04 Matsushita Electric Industrial Co., Ltd. Antiviral composition
IT1277707B1 (it) * 1995-12-22 1997-11-11 Chemedica Sa Formulazione oftalmica a base di ialuronato di sodio per uso nella chirurgia oculare
JP4138910B2 (ja) * 1997-07-02 2008-08-27 帝國製薬株式会社 経皮吸収性が良好で且つ皮膚刺激性の少ない塩酸アゼラスチン含有経皮製剤
RU2149611C1 (ru) 1998-04-06 2000-05-27 Московская медицинская академия им. И.М. Сеченова Капли для лечения воспалительных заболеваний глаз (варианты)
DE19954516A1 (de) * 1999-11-12 2001-05-17 Boehringer Ingelheim Int Epinastin-haltige Lösungen
US6258814B1 (en) * 2000-10-13 2001-07-10 Schering Corporation Method of using cetirizine and pharmaceutical compositions containing the same for inducing sleep
US8877168B1 (en) * 2002-07-31 2014-11-04 Senju Pharmaceuticals Co., Ltd. Aqueous liquid preparations and light-stabilized aqueous liquid preparations
KR20060040676A (ko) * 2003-07-11 2006-05-10 미리어드 제네틱스, 인크. 알츠하이머병을 치료하기 위한 약제학적 방법, 투약 방법및 제형
FI119361B (fi) 2003-09-26 2008-10-31 Raute Oyj Menetelmä viilun sorvaamiseksi
US20060073172A1 (en) * 2004-10-01 2006-04-06 Schneider L W Stabilized ophthalmic solution for the treatment of glaucoma and lowering intraocular pressure
PL2444079T3 (pl) * 2005-05-17 2017-07-31 Sarcode Bioscience Inc. Kompozycje i sposoby leczenia chorób oczu
EP1901708B1 (en) * 2005-07-08 2013-09-11 Senju Pharmaceutical Co., Ltd. Percutaneously absorptive ophthalmic preparation comprising olopatadine
US7544893B2 (en) 2007-07-25 2009-06-09 Thomas & Betts International, Inc. Extruded wire duct end cap
ITRM20080182A1 (it) * 2008-04-07 2009-10-08 Medivis S R L Preparato oftalmico a base di dorzolamide e latanoprost per il trattamento topico del glaucoma.
WO2009139817A2 (en) * 2008-04-15 2009-11-19 Sarcode Corporation Crystalline pharmaceutical and methods of preparation and use thereof
WO2009128933A1 (en) * 2008-04-15 2009-10-22 Sarcode Corporation Aerosolized lfa-1 antagonists for use in localized treatment of immune related disorders
US20090258070A1 (en) 2008-04-15 2009-10-15 John Burnier Topical LFA-1 antagonists for use in localized treatment of immune related disorders
WO2010033800A2 (en) * 2008-09-19 2010-03-25 Alacrity Biosciences, Inc. Tetracycline stabilizing formulations
CN102176920B (zh) * 2008-11-17 2013-09-18 莱拉制药用品私营有限责任公司 姜黄素及其用于治疗眼科疾病的方法
MX2011013150A (es) * 2009-06-10 2012-03-14 Ltd Liability Company Mitotech Composicion farmaceutica para uso en oftalmologia medica y veterinaria.
KR20110001103A (ko) 2009-06-29 2011-01-06 에스케이케미칼주식회사 보관 안정성이 향상된 톨테로딘 함유 경피 투여 조성물
CA2781698A1 (en) * 2009-11-23 2011-05-26 Allergan, Inc. 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
US20120190653A1 (en) * 2011-01-20 2012-07-26 Dow Pharmaceutical Sciences, Inc. Therapeutic eye drop comprising doxycycline and a stabilizer
EP2675455A4 (en) * 2011-02-18 2014-07-16 M S Appasamy Associates OPHTHALMIC COMPOSITION FOR DILATING PUPILS
AU2012275113A1 (en) * 2011-06-29 2014-01-30 Allergan, Inc. Alcaftadine for use in the treatment of urticaria
WO2013148896A1 (en) * 2012-03-29 2013-10-03 Cxl Ophthalmics, Llc Ocular treatment solutions, delivery devices and delivery augmentation methods
CN103230583A (zh) * 2013-05-17 2013-08-07 江西省创欣药业集团有限公司 兽用治疗肠道疾病的烟酸诺氟沙星复方注射液及制备方法

Also Published As

Publication number Publication date
IL239490B (en) 2018-12-31
MX2019012375A (es) 2020-01-20
US11058677B2 (en) 2021-07-13
MX368876B (es) 2019-10-21
DK2934510T3 (da) 2021-01-25
PL2934510T3 (pl) 2021-07-05
WO2014100135A1 (en) 2014-06-26
EA201591180A1 (ru) 2015-12-30
AU2013361579B2 (en) 2018-05-24
MX2015007540A (es) 2016-04-13
HUE052299T2 (hu) 2021-04-28
AU2013361579A1 (en) 2015-06-18
KR20150100763A (ko) 2015-09-02
NZ708821A (en) 2020-03-27
CA2894170A1 (en) 2014-06-26
JP6373867B2 (ja) 2018-08-15
US20150320737A1 (en) 2015-11-12
ZA201608069B (en) 2017-11-29
BR112015014367B1 (pt) 2022-11-22
EP3827823A1 (en) 2021-06-02
ES2846724T3 (es) 2021-07-29
EP2934510A4 (en) 2016-08-17
CN104955453A (zh) 2015-09-30
IL239490A0 (en) 2015-08-31
SI2934510T1 (sl) 2021-02-26
US20220000859A1 (en) 2022-01-06
KR101891144B1 (ko) 2018-08-23
EP2934510B1 (en) 2020-10-28
EA028008B1 (ru) 2017-09-29
HK1214963A1 (zh) 2016-08-12
ZA201504404B (en) 2020-01-29
PT2934510T (pt) 2021-01-13
HK1214536A1 (zh) 2016-07-29
EP2934510A1 (en) 2015-10-28
CA2894170C (en) 2021-08-10
CN104955453B (zh) 2018-09-18
JP2016503058A (ja) 2016-02-01
EA201791321A1 (ru) 2018-04-30

Similar Documents

Publication Publication Date Title
BR112016020199A8 (pt) composto inibidor de calicreína plasmática de humano, composição farmacêutica compreendendo o referido composto, kit e seu uso
BR112014026703A2 (pt) inibidores de dna-pk
BR112012029517A2 (pt) formulações de fragrância, métodos de fabricação e artigos compreendendo as mesmas.
EA201691590A1 (ru) Бензимидазол-2-амины в качестве ингибиторов midhi
BR112015022191A2 (pt) compostos heteroarila, seu uso e composição que os compreende
BR112014022000A8 (pt) compostos à base de pirazol[1,5-a]pirimidina, seu uso e composições que os compreende
BR112013028430A2 (pt) composto, composição farmacêutica, método para tratar uma doença ou condição mediada por tirosina quinase do baço (syk), e, uso de uma quantidade terapeuticamente eficiente do composto
BR112014001801A2 (pt) indazóis
WO2012142511A3 (en) Orthomolecular compositions and their use in stabilizing the extracellular matrix
BR112019024747A2 (pt) formulações de dose fixa
BR112014021531A2 (pt) composto, composição farmacêutica e usos dos mesmos
ECSP12012318A (es) Inhibidores de pirazolil quinazolina cinasa
BR112014007163A2 (pt) composições farmacêuticas de n-metil-2 [3 ((e)-2 piridin-2 il-vinil)-1h-indazol-6 ilsulfanil]-benzamida
BR112016028845A2 (pt) composto, composição farmacêutica e uso de um composto
BR112014000792A2 (pt) compostos de piperidinila para uso como inibidores da tanquirase
BR112015020139A2 (pt) compostos terapêuticos e usos dos mesmos
BR112018070123A2 (pt) oxiesterós e métodos de uso dos mesmos
BR112014028042A2 (pt) inibidores de nampt
DOP2015000170A (es) Compuestos químicos
BR112013001632A2 (pt) composto, composição farmacêutica, método de inibir uma atividade uma jak quinase in vitro, uso de um composto, ou da composição farmacêutica, e, método de fabricar um composto
DOP2014000059A (es) Derivados de estra–1,3,5(10),16–tetraen–3–carboxamida, procedimientos para su preparación, preparados farmacéuticos que los contienen, así como su uso para la preparación de medicamentos
EA201590183A1 (ru) Производные азаиндола, выступающие в качестве ингибиторов pi3k
BR112015019412A2 (pt) inibidores de bace1
CL2015000039A1 (es) Derivados estra-1,3,5(10),16-tetraeno-3-sustituidos, preparaciones farmacéuticas que los comprenden y su uso en la preparación de medicamentos para tratar la endometriosis.
BR112017022158A2 (pt) compostos, composições farmacêuticas e uso de um composto

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06F Objections, documents and/or translations needed after an examination request according [chapter 6.6 patent gazette]
B06I Publication of requirement cancelled [chapter 6.9 patent gazette]

Free format text: ANULADA A PUBLICACAO CODIGO 6.6.1 NA RPI NO 2462 DE 13/03/2018 POR TER SIDO INDEVIDA.

B07E Notification of approval relating to section 229 industrial property law [chapter 7.5 patent gazette]

Free format text: NOTIFICACAO DE ANUENCIA RELACIONADA COM O ART 229 DA LPI

B06U Preliminary requirement: requests with searches performed by other patent offices: procedure suspended [chapter 6.21 patent gazette]
B25A Requested transfer of rights approved

Owner name: NOVARTIS AG (CH)

B06A Patent application procedure suspended [chapter 6.1 patent gazette]
B09A Decision: intention to grant [chapter 9.1 patent gazette]
B16A Patent or certificate of addition of invention granted [chapter 16.1 patent gazette]

Free format text: PRAZO DE VALIDADE: 20 (VINTE) ANOS CONTADOS A PARTIR DE 18/12/2013, OBSERVADAS AS CONDICOES LEGAIS